Nascent Biotech Announces $225,000 NIH Grant Award in Conjunction with Mapp Biopharmaceutical
San Diego, CA, February 26th, 2015 – Nascent Biotech, Inc. (OTC: NBIO) and Mapp Biopharmaceutical announced today they have been awarded a $225,000 Small Business Innovative Research (SBIR) grant, titled “Novel Immunotherapy for Brain Cancer,” to fund initial development of tobacco plants as an adjunct expression system for Nascent Biotech’s lead candidate biopharmaceutical, Pritumumab, a monoclonal antibody for the treatment of brain cancer.
This grant is a collaboration between Nascent Biotech and Mapp Biopharmaceutical, a technology leader in plant-based manufacturing of monoclonal antibodies.
Dr. Mark Glassy of Nascent says, “This grant will help accelerate the development and manufacturing of potentially life-saving antibody treatments for patients suffering from brain cancer.” Adding, “We are extremely pleased to have Mapp as a partner, as they are evaluating the therapeutic benefits of this novel expression system in clinical trials.”
“Mapp is delighted to partner with Nascent Biotech in developing a very promising cancer therapy antibody. The opportunity to make a cost effective treatment accessible to all emerging market countries, is compelling” says Dr. Kevin Whaley, Mapp CEO.
About Nascent Biotech, Inc.:
Nascent Biotech, Inc is a clinical-stage biotech company engaged in the development of monoclonal antibodies to be used in the treatment of various cancers. Its products are not commercially available. For further information please visit our website www.nascentbiotech.com.
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals; Nascent Biotech Inc’s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on October 28, 2014, and future filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
Nascent Biotech, Inc.